Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Free Report) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 20,626 shares, a growth of 232.5% from the August 15th total of 6,203 shares. Based on an average daily trading volume, of 17,353 shares, the short-interest ratio is currently 1.2 days.
Algernon Pharmaceuticals Price Performance
AGNPF stock opened at $0.37 on Monday. The company’s 50-day simple moving average is $0.32 and its 200-day simple moving average is $0.23. Algernon Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $0.64.
About Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.
The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).
Featured Stories
- Five stocks we like better than Algernon Pharmaceuticals
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
